undamentalytics Newsletter
Sign in

Perspective Therapeutics, Inc. (CATX) stock

Add to watchlist

Add holding +

NYSE: CATX NYSE Biotechnology Next results ~November 9, 2026

Perspective Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Perspective Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 1 selling2 purchases and 2 sales by directors and officers, last 12 monthsInsider trades
  • Funds83 adding, 55 cuttingOf 28 active managers that changed their stake, 18 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Current signal Gross margin expanding: TTM gross margin reached 100.0%, up 73.6pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 84.0% over the last 12 months.
  • Growth slowing. The growth rate is 66.1 points lower than a quarter earlier.
  • Loss-making. Operating margin is -2855.0%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 2753.5 points on a year ago.
  • Burning cash. Free cash flow was -2648.9% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 248.0% of revenue: a real cost that cash-flow figures leave out.

Latest results: FY2023 Q4

Filed March 28, 2024
Earnings per share
-$0.22 against an average estimate of -$0.27: beat by 19.0%
Share reaction
+6.0% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
Next report
November 9, 2026; average EPS estimate -$0.25

Perspective Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-9.6%
  • 1 week-14.0%
  • 1 month-62.3%
  • This year-62.2%
  • 1 year-61.9%
  • 5 years-84.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-1.25

Growth

Share count change
+29.4%

Earnings

Last results
August 10, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Announcement
  5. Announcement
  6. Results
  7. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Perspective Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

13 /100

Weak moat

How hard Perspective Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -30.1% of total assets over 10 years.

  • Pricing power 4 / 20

    Gross margin has been a median 32.3%, moving by 28.9 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -100.9%; its worst year was -2855.0%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -82.0% of revenue.

  • Discipline 4 / 20

    The diluted share count rose 1279.1% over five years; stock-based pay has been a median 6.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (18 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, after the close. Analysts expect revenue of $47810 and EPS of −$0.25 (range −$0.31 to −$0.22) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.99 +30% $299000 −66%
Next −$1.03 −4% $314550 +5%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −12.1% on 90 days ago. In the last 30 days, 6 analysts raised Perspective Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Perspective Therapeutics, Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.12 Current fiscal year, 60 days ago: −$0.99 Current fiscal year, 30 days ago: −$0.98 Current fiscal year, 7 days ago: −$0.99 Current fiscal year, Now: −$0.99 −$0.99 Next fiscal year, 90 days ago: −$1.13 Next fiscal year, 60 days ago: −$1.02 Next fiscal year, 30 days ago: −$1.02 Next fiscal year, 7 days ago: −$1.04 Next fiscal year, Now: −$1.03 −$1.03

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.12−$1.13
60 days ago −$0.99−$1.02
30 days ago −$0.98−$1.02
7 days ago −$0.99−$1.04
Now −$0.99−$1.03

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.27 −$0.22 +19.0%
Mar 2026 −$0.32 −$0.25 +21.7%
Dec 2025 −$0.34 −$0.51 −47.1%
Sept 2025 −$0.32 −$0.35 −8.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

16 analysts, Oct 2026
Buy1488%
Hold213%
Sell00%

Monthly trend

  1. Oct 202613216
  2. Sep 202621316
  3. Aug 202621215
  4. Jul 202621215

Counts of recommendations published by analysts covering Perspective Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
17.4%
of tradable shares
Days to cover
6.96
at average volume
Short interest, 1 month
−27%
to October 15, 2026
Held by institutions
86%
of shares
Held by insiders
8.2%
of shares
Employees
163
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CATX−13%−36%+60%−20%−14%−62%
Industry peers (median)−36%−57%−18%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CATX8%50%33%50%58%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CATX−85%−49%−71%−85%−59%−82%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 96% from January 20, 2021 to November 2, 2026. Getting back needed a 2275% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.04 – $5.65
From 52-week high
−81.6%
vs 50-day average
−58.8%
vs 200-day average
−70.6%
Volatility (1 year)
110%
Beta vs S&P 500
1.57

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±10.2%
After a week
6 up, 6 down
typical move ±12.4%
After a month
4 up, 8 down
typical move ±23.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 10, 2026 +6.0% −0.3% +7.3% −0.3%
May 11, 2026 +0.3% +0.1% 0.0% −21.5%
May 4, 2026 −5.2% +0.4% +0.8% −7.5%
March 16, 2026 −1.0% +1.3% −15.2% −12.4%
February 2, 2026 +37.2% −0.4% +27.7% +39.1%
January 9, 2026 −14.2% +0.8% −17.1% +68.7%
November 10, 2025 +1.4% +1.8% +0.9% +16.4%
October 20, 2025 −30.7% +1.0% −31.0% −49.2%
August 13, 2025 −2.0% +0.4% −15.1% −12.6%
May 12, 2025 +8.5% +4.0% +16.2% +39.6%
March 26, 2025 −6.9% −1.5% −17.0% −3.2%
January 13, 2025 −8.6% +0.3% +0.6% −13.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Perspective Therapeutics, Inc.
$0 $5M $10M $15M FY21 Q1 FY21 Q4 FY22 Q3 FY23 Q4 Revenue (TTM), FY21 Q1: $9.6M Revenue (TTM), FY21 Q2: $10.1M Revenue (TTM), FY21 Q3: $10.2M Revenue (TTM), FY21 Q4: $10.7M Revenue (TTM), FY22 Q1: $11M Revenue (TTM), FY22 Q2: $10.8M Revenue (TTM), FY22 Q3: $9.9M Revenue (TTM), FY22 Q4: $9M Revenue (TTM), FY23 Q1: $8.1M Revenue (TTM), FY23 Q2: $7.7M Revenue (TTM), FY23 Q3: $8.2M Revenue (TTM), FY23 Q4: $1.4M $1.4M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY21 Q1 $9.6M
FY21 Q2 $10.1M
FY21 Q3 $10.2M
FY21 Q4 $10.7M
FY22 Q1 $11M
FY22 Q2 $10.8M
FY22 Q3 $9.9M
FY22 Q4 $9M
FY23 Q1 $8.1M
FY23 Q2 $7.7M
FY23 Q3 $8.2M
FY23 Q4 $1.4M
Revenue growth, TTM YoY Perspective Therapeutics, Inc.
-100% -50% 0% 50% FY21 Q1 FY21 Q4 FY22 Q3 FY23 Q4 Revenue growth, TTM YoY, FY21 Q1: 3.2% Revenue growth, TTM YoY, FY21 Q2: 3.9% Revenue growth, TTM YoY, FY21 Q3: 5.0% Revenue growth, TTM YoY, FY21 Q4: 8.0% Revenue growth, TTM YoY, FY22 Q1: 14.3% Revenue growth, TTM YoY, FY22 Q2: 7.4% Revenue growth, TTM YoY, FY22 Q3: -2.8% Revenue growth, TTM YoY, FY22 Q4: -16.1% Revenue growth, TTM YoY, FY23 Q1: -26.2% Revenue growth, TTM YoY, FY23 Q2: -28.6% Revenue growth, TTM YoY, FY23 Q3: -17.9% Revenue growth, TTM YoY, FY23 Q4: -84.0% -84.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY21 Q1 3.2%
FY21 Q2 3.9%
FY21 Q3 5.0%
FY21 Q4 8.0%
FY22 Q1 14.3%
FY22 Q2 7.4%
FY22 Q3 -2.8%
FY22 Q4 -16.1%
FY23 Q1 -26.2%
FY23 Q2 -28.6%
FY23 Q3 -17.9%
FY23 Q4 -84.0%
Operating margin (TTM) Perspective Therapeutics, Inc.
-3000% -2000% -1000% 0% FY21 Q1 FY21 Q4 FY22 Q3 FY23 Q4 Operating margin (TTM), FY21 Q1: -36.8% Operating margin (TTM), FY21 Q2: -34.3% Operating margin (TTM), FY21 Q3: -48.9% Operating margin (TTM), FY21 Q4: -54.0% Operating margin (TTM), FY22 Q1: -58.0% Operating margin (TTM), FY22 Q2: -68.5% Operating margin (TTM), FY22 Q3: -93.7% Operating margin (TTM), FY22 Q4: -101.5% Operating margin (TTM), FY23 Q1: -215.4% Operating margin (TTM), FY23 Q2: -326.3% Operating margin (TTM), FY23 Q3: -375.4% Operating margin (TTM), FY23 Q4: -2855.0% -2855.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY21 Q1 -36.8%
FY21 Q2 -34.3%
FY21 Q3 -48.9%
FY21 Q4 -54.0%
FY22 Q1 -58.0%
FY22 Q2 -68.5%
FY22 Q3 -93.7%
FY22 Q4 -101.5%
FY23 Q1 -215.4%
FY23 Q2 -326.3%
FY23 Q3 -375.4%
FY23 Q4 -2855.0%
FCF margin (TTM) Perspective Therapeutics, Inc.
-3000% -2000% -1000% 0% FY21 Q1 FY21 Q4 FY22 Q3 FY23 Q4 FCF margin (TTM), FY21 Q1: -29.7% FCF margin (TTM), FY21 Q2: -32.0% FCF margin (TTM), FY21 Q3: -47.9% FCF margin (TTM), FY21 Q4: -51.2% FCF margin (TTM), FY22 Q1: -56.5% FCF margin (TTM), FY22 Q2: -73.9% FCF margin (TTM), FY22 Q3: -77.3% FCF margin (TTM), FY22 Q4: -119.1% FCF margin (TTM), FY23 Q1: -235.9% FCF margin (TTM), FY23 Q2: -321.8% FCF margin (TTM), FY23 Q3: -407.2% FCF margin (TTM), FY23 Q4: -2648.9% -2648.9%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY21 Q1 -29.7%
FY21 Q2 -32.0%
FY21 Q3 -47.9%
FY21 Q4 -51.2%
FY22 Q1 -56.5%
FY22 Q2 -73.9%
FY22 Q3 -77.3%
FY22 Q4 -119.1%
FY23 Q1 -235.9%
FY23 Q2 -321.8%
FY23 Q3 -407.2%
FY23 Q4 -2648.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-KT, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Jun 2011 2012 Jun 2012 2013 Jun 2013 2014 Jun 2014 2015 Jun 2015 2016 Jun 2016 2017 Jun 2017 2018 Jun 2018 2019 Jun 2019 2020 Jun 2020 2021 Jun 2021 2022 Dec 2022 2023 Dec 2023
Income
Revenue 5 5 5 4 5 5 5 6 7 10 10 0 1
Gross profit 1 1 0 −0 0 0 1 2 3 5 5 — 1
EBITDA −2 −3 −3 −4 −4 −5 −6 −7 −5 −3 −3 — −40
Operating income −3 −4 −4 −5 −4 −5 −6 −7 −5 −3 −3 — −41
Net income −3 −3 −4 −6 −4 −5 −6 −7 −5 −3 −3 — −47
Diluted EPS −$1.10 −$1.20 −$0.11 −$1.60 −$0.70 −$0.90 −$1.10 −$1.20 −$0.80 −$0.05 −$0.30 — −$1.74
Growth (year on year)
Revenue — −3.2% −10.8% −6.8% +9.2% +3.5% −0.2% +24.4% +23.5% +32.3% +3.9% −100.0% —
Margins
Gross margin 22.1% 13.9% 3.3% −4.7% 3.6% 2.7% 17.6% 31.1% 41.7% 52.9% 50.9% — 100.0%
EBITDA margin −39.6% −54.2% −73.5% −92.5% −81.7% −96.7% −131.0% −112.3% −70.0% −34.4% −32.8% — <−999%
Operating margin −56.6% −71.0% −89.9% −108.7% −94.2% −106.6% −132.5% −113.6% −71.8% −35.9% −34.3% — <−999%
Net margin −54.3% −68.8% −85.2% −141.2% −79.9% −98.8% −129.4% −113.1% −70.3% −35.6% −33.7% — <−999%
Free-cash-flow margin −48.8% −49.4% −67.7% −77.0% −79.4% −91.5% −131.5% −102.1% −75.1% −40.4% −32.0% — <−999%
Cash flow
Cash from operations −2 −2 −3 −3 −4 −4 −6 −6 −5 −4 −3 — −37
Capital spending 0 0 0 0 0 0 1 0 0 0 0 0 1
Free cash flow −3 −3 −3 −3 −4 −4 −6 −6 −5 −4 −3 — −38
Stock-based pay 0 0 0 0 0 0 0 0 0 0 0 — 4
Free cash flow after stock pay −3 −3 −3 −3 −4 −5 −7 −6 −6 −4 −4 — −42
Balance sheet
Cash — — — — — — — — — — — 21 9
Total debt 0 0 0 0 0 0 0 0 0 0 0 0 2
Net debt (negative = net cash) — — — — — — — — — — — −21 −7
Diluted shares 3m 3m 3m 4m 5m 6m 6m 6m 7m 7m 10m — 27m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

Diluted share count
+29.4%
year over year

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated CATX RNAC DARE ABSI OVID LGVN Median
Revenue, last 12 months $1m $1m $1m $2m $2m $1m $55m
Revenue growth, last 12 months −84.0% 44.0% >999% −62.3% −76.2% −42.7% 12.2%
Revenue growth, 3-year average −47.5% −68.8% — −43.3% 99.8% 10.4% 13.1%
Revenue growth, latest quarter 27.3% −100.0% 499.6% −46.4% −88.3% −9.2% 10.2%
Gross margin 100.0% — — — — 69.8% 82.9%
Operating margin <−999% <−999% −813.4% <−999% <−999% <−999% −191.1%
Operating margin, 3-year average <−999% <−999% >999% <−999% <−999% <−999% −365.3%
Net margin <−999% <−999% −804.4% <−999% <−999% <−999% −172.8%
Cash from operations / revenue <−999% <−999% −826.8% <−999% <−999% <−999% −168.8%
Free-cash-flow margin <−999% <−999% −860.6% <−999% <−999% <−999% −168.1%
Free-cash-flow margin, 3-year average −939.8% <−999% >999% <−999% <−999% <−999% −313.4%
Stock pay / revenue 248.0% 625.6% 110.0% >999% 302.0% 132.8% 20.7%
Change in share count 29.4% 143.3% 62.5% 26.0% 0.5% — 8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$305M
Institutions reporting
130
Shares held vs prior quarter
▲ 5.5%
Positions opened / closed
23 / 29

Top buyers and sellers, Q2 2026: 83 institutions bought and 55 sold ; the biggest buyer was Nantahala Capital Management, LLC (+4.7M shares) and the biggest seller Avidity Partners Management LP (−5.8M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $32.4M 9.5M 10.6% ▲ 77.5%
Tcg Crossover Management, LLC $27M 7.9M 8.9% 0.0%
Commodore Capital LP $21.6M 6.3M 7.1% 0.0%
Avidity Partners Management LP $21.5M 6.3M 7.1% ▼ 47.9%
State Street Corp $20.6M 6.1M 6.8% ▲ 93.2%
Millennium Management LLC $16.7M 4.9M 5.5% ▲ 21.4%
Nantahala Capital Management, LLC $15.9M 4.7M 5.2% New
Vanguard Capital Management LLC $15.1M 4.4M 5.0% ▲ 1.3%
Affinity Asset Advisors, LLC $14.4M 4.2M 4.7% ▲ 33.2%
Citadel Advisors LLC $13M 3.8M 4.3% ▲ 6.7%
Spruce Street Capital LP $12.6M 3.7M 4.1% ▲ 40.6%
Balyasny Asset Management L.P. $11.3M 3.3M 3.7% ▲ 10.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Perspective Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $42,276 2 trades by 2 insiders, last 12 months Insider sales History → $356,975 2 trades by 1 insider · 0% under pre-set plans
Net ▼ $314,699 net selling
Insider Date Trade Shares Price Value
Lantheus Alpha Therapy, Llc 10% owner September 1, 2026 Sell 35,769 $3.12 $111,599
Lantheus Alpha Therapy, Llc 10% owner August 31, 2026 Sell 78,145 $3.14 $245,375
Hunt Jonathan Robert Chief Accounting Officer November 13, 2025 Buy 11,000 $2.03 $22,330
Williamson Robert F Iii Director November 12, 2025 Buy 9,498 $2.10 $19,946

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 10, 2026
  • May 11, 2026
  • May 4, 2026
  • March 16, 2026
  • February 2, 2026
  • January 9, 2026

Recent SEC filings

Data status

When each part of this page on Perspective Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Perspective Therapeutics, Inc. in brief

What does Perspective Therapeutics, Inc. do?
Perspective Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Perspective Therapeutics, Inc.'s stock ticker?
Perspective Therapeutics, Inc. trades under the ticker CATX on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Perspective Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Tcg Crossover Management, LLC and Commodore Capital LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Perspective Therapeutics, Inc.'s market cap?
On December 29, 2023, Perspective Therapeutics, Inc.'s market capitalisation was about $107M and net debt of -$7.5M. Market figures come from third-party market data and may be delayed.
Who are Perspective Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Perspective Therapeutics, Inc. are Cartesian Therapeutics, Inc., Dare Bioscience, Inc., Absci Corp, Ovid Therapeutics Inc. and Longeveron Inc. The side-by-side comparison below sets their revenue, margins and growth against Perspective Therapeutics, Inc.'s.
Are insiders buying or selling Perspective Therapeutics, Inc. stock?
Over the last 12 months, Perspective Therapeutics, Inc.'s directors and officers reported 2 open-market purchases and 2 sales on Form 4. The insider trading page charts every trade.
When is Perspective Therapeutics, Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Perspective Therapeutics, Inc. announces its own schedule.